What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.8% in the afternoon session after the stock's ...

Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases. The ...

Moderna (MRNA) is back in the spotlight after securing up to $54.3 million from CEPI to help fund a Phase 3 trial of its H5 ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...

HHS Secretary Robert F. Kennedy Jr. doesn't believe mRNA vaccines for COVID-19 and flu work, so funding is shifting to virus-based vaccines Moderna's stock fell Wednesday after Health and Human ...

Moderna (NASDAQ:MRNA) is scheduled to announce Q2 earnings results on Friday, August 1st, before market open. The consensus EPS Estimate is -$3.00 and the consensus revenue estimate is $112.56M (-53.3 ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug substance plant in Japan. The vaccine maker opted to scrap the project ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court’s finding of noninfringement in favor of Moderna, Inc. (NASDAQ:MRNA) in its ongoing patent battle with ...

NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the ...